CA 125 is an indicator for pleural metastases in breast cancer

Anticancer Research

Volumn 17, Issue 4 B, 1997, Pages 2967-2970

  Kramer S ^a   Jager W ^a   Lang, N ^a  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

Author keywords

Breast cancer; CA 125; Metastases; Ovarian cancer; Pleural metastases

Indexed keywords

CA 125 ANTIGEN;

BLOOD LEVEL; BREAST CANCER; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; ENZYME LINKED IMMUNOSORBENT ASSAY; FOLLOW UP; HUMAN; LUNG METASTASIS; MAJOR CLINICAL STUDY; PLEURA EFFUSION; PLEURA METASTASIS; PRIORITY JOURNAL;

BREAST NEOPLASMS; CA-125 ANTIGEN; FEMALE; HUMANS; PLEURAL NEOPLASMS;

EID: 1842366681     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (16)

1. Bast RC, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths, CT, Parker L, Zurawski VR, Knapp RC: A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 309: 169-171, 1983.
2. Einhorn N, Bast RC, Knapp RC, Tjernberg B, Zurawski VR: Preoperative evaluation of serum CA 125 levels in patients with primary epithelial ovarian cancer. Obstet Gynecol 67: 414-416, 1986.
3. Jäger W, Kissing A, Cilaci S, Melsheimer R, Lang N: Is an increase in CA 125 in breast cancer patients an indicator of pleural metastases? Br J Cancer 70: 493-495, 1994.
4. Hayward JL, Rubens RD, Carbone PP, Heuson JC, Kumaoka S, Segaloff A: Assessment of response to therapy in advanced breast cancer: a project of the programme on clinical oncology of the International Union against cancer, Geneva, Switzerland. Br J Cancer 35: 292-298, 1977.
5. Eissa S, Khalifa A, Abo-Ghalia A., Abdalla H: Expression of CA 125 in Breast Cancer. In: R. Klapdor (ed) Tumor Associated Antigens, Oncogenes, Receptors, Cytokines in Tumor Diagnosis and Therapy at the Beginning of the Nineties, Cancer of the Breast - State and Trends in Diagnosis and Therapy. W. Zuckschwerdt Verlag Munchen, Bern ,Wien, New York, 1992.
6. Kabawat SE, Bast RC, Welch WR, Knapp RC, Colvin RB: Immunopathologic characterization of a monoclonal antibody that recognizes common surface antigens of human ovarian tumors of serous, endometrioid, and clear cell types. Am J Clin Paythol 79: 98, 1983.
7. Kabawat SE, Bast RC, Bhan AK, Welch WR, Knapp RC, Colvin RB: Tissue distribution of a coelomic-epithelium-related antigen recognized by the monoclonal antibody OC 125. Int J Gynecol Pathol 2: 275-285, 1983.
8. Zeimet AG, Offner FA, Feichtinger H, Marth C, Dapunt O: Human peritoneal mesothelial cells are more potent in producing tumor marker CA 125 than ovarian cancer cells. Anticancer Res 15/6A: 2381, 1995.
9. Nouwen RL Pollet CE, Eerdekens MW, Hendrix PG, Briers TW, DeBroe ME: Immunohistochemical localization of placental alkaline phosphatase, carcinoembryonic antigen and cancer antigen CA 125 in normal and neoplastic human lung. Cancer Res 46: 6143-6148, 1986.
10. Diez M, Cerdan FJ, Ortega MD, Torres A, Picardo A, Balibrea JL: Evaluation of serum CA 125 as a tumor marker in non-small cell lung cancer. Cancer 67: 150-154, 1991.
11. Van Niekerk CC, Jap PHK, Thomas CMG, Smeets DFCM, Ramaekers FCS, Poels LGC: Marker profile of mesothelial cells versus ovarian carcinoma cells. Int J Cancer 43: 1065-1071, 1989.
12. Chernow B, Sahn SA: Carcinomatose involvement of the pleura: An analysis of 96 patients. Am J Med 63: 695-702, 1977.
13. Ruibal A, Encabo G, Marinez-Miralles E, Murcia C, Capdevila JA, Salgado A, Martinez-Vasquez JM: CA 125 serie levels in non malignant pathologies. Bull Bancer 71: 145-148, 1984.
14. Pinto MM, Bernstein LH, Rosser AR, Brogan DA, Rosman M: Diagnostic efficiency of carcinoembryonic antigen and CA 125 in the cytological evaluation of effusions. Arch Pathol Lab Med 116: 626-631, 1992.
15. Böhmer C, Jäger W, Läng N: CA 125 measurement in the follow-up of breast cancer patients. Anticancer Res 15/6A: 2388, 1995.
16. Jäger W, Krämer S, Palapelas V, Lang N: Breast cancer and clinical utility of CA 15-3 and CEA. Scand J Clin Lab Invest 55: 87-92, 1995.